Last reviewed · How we verify
NCT03324555
Study of ORIC-101 in Healthy Adult Subjects
Phase 1 trial testing ORIC-101 in Healthy Volunteers in 24 participants. Completed in 18 December 2017.
18 December 2017
Quick facts
| Lead sponsor | ORIC Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 19 October 2017 |
| Primary completion | 18 December 2017 |
| Estimated completion | 18 December 2017 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ORIC-101 — full drug profile →
Conditions studied
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
ORIC Pharmaceuticals — full company profile →
Who can join
Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
ORIC-GR-17001 is an open-label, single center, non-randomized, single ascending dose study in healthy male subjects and healthy female subjects of non-child bearing potential. In this study, ORIC-101 will be administered as single-ascending oral doses. The primary objective is to characterize the safety and tolerability of oral ORIC-101.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03324555
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ORIC-101
Trials testing the same drug.
- NCT04033328 — Study of ORIC-101 in Combination With Enzalutamide · Phase 1 · terminated
- NCT03928314 — Study of ORIC-101 in Combination With Anticancer Therapy · Phase 1 · terminated
- NCT03835637 — Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects · Phase 1 · completed
Other recruiting trials for Healthy Volunteers
Currently open trials in the same condition.
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
- NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
Other ORIC Pharmaceuticals trials
Trials by the same sponsor.
- NCT06012721 — Effect of Food on the Pharmacokinetics of ORIC-114 · Phase 1 · completed
- NCT05227144 — Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma · Phase 1 · completed
- NCT04033328 — Study of ORIC-101 in Combination With Enzalutamide · Phase 1 · terminated
- NCT03928314 — Study of ORIC-101 in Combination With Anticancer Therapy · Phase 1 · terminated
- NCT03835637 — Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03324555 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ORIC Pharmaceuticals
- Last refreshed: 5 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03324555.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing